主要参考文献：

1.  Li K,  Wang F，Cao WB,  and ZW et al (2017)  TRIB3 Promotes APL Progression
through Stabilization of the Oncoprotein PML-RARa and Inhibition of p53-Mediated Senescence. Cancer Cell 31, 697–710

2. Tang X，Shi L，and Liu B et al (2017) SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis. Nature Communications 8: 318

1. Liu C, Ren YF,  Yi Lv and Xu-Feng Zhan et al (2017) Activation of SRY Accounts for Male-Specific Hepatocarcinogenesis: Implication in Gender Disparity of Hepatocellular Carcinoma. Cancer Letters 410: 20-31

3. Chunga WJ,  Daemena A, Melissa R, and Junttila MR et al (2017) Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous. PNAS Dec 4, E10947–E10955

4. Annunziato S, Kas SM, Nethe M, and Drenth AP et al (2016) Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev 30: 1470 – 1480

5. Drost R, Dhillon KK, and Schut E et al (2016) BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest 126: 2903 – 2918

6. Maresch R, Mueller S, and Barenboim M et al (2016) Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/ Cas9 delivery in mice. Nat Commun 7: 10770

7. Chiou SH, Winters IP, Wang J,  and Chuang CH et al (2015) Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev 29: 1576 – 1585

8. Weber J, Öllinger R, and Engleitner T et al (2015) CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc Natl Acad Sci USA 112: 13982 – 13987

9. Dow LE, O’Rourke KP,  and Lowe SW et al (2015b) Apc restoration promotes cellular differentiation and reestablishes Crypt homeostasis in colorectal cancer. Cell 161:1539 – 1552

10. Henneman L, van Miltenburg MH, and Schlicker A et al (2015) Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc Natl Acad Sci USA 112: 8409 – 8414

11. Clohessy JG, Pandolfi PP (2015) Mouse hospital and co-clinical trial project- from bench to bedside. Nat Rev Clin Oncol 12: 491 – 498

12. Cong L, Ran FA, Cox D,  and Marraffini LA et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819 – 823

13. Jamieson T, Clarke M, and Nibbs RJB et al (2012) Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 122: 3127 – 3144

14. Drake AC, Chen Q, Chen J (2012) Engineering humanized mice for improved hematopoietic reconstitution. Cell Mol Immunol 9: 215 – 224

15. Liu P, Cheng H, and Fox EA et al (2011) Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway- independent mechanisms. Nat Med 17: 1116 – 1120

16. Martins CP, Brown-Swigart L, and Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323 – 1334

17.  Shibata H, Toyama K, Shioya H, and Toyoshima K et al (1997) Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278: 120 – 123